<DOC>
	<DOC>NCT00495339</DOC>
	<brief_summary>Estimate of clinical and microbiological efficacy of Levofloxacin (Tavanic) in combine therapy of MDR TB. Estimate of safety of Levofloxacin (Tavanic) in combine therapy of MDR TB.</brief_summary>
	<brief_title>MDR TB, Levofloxacin, Multi-Drug-Resistant Pulmonary Tuberculosis</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis, Pulmonary</mesh_term>
	<mesh_term>Tuberculosis, Multidrug-Resistant</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<criteria>Drugresistant pulmonary tuberculosis laboratory diagnosed Known hypersensitivity to levofloxacin, other quinolones Patient with epilepsy and central nervous system diseases Renal insufficiency with serum creatinine lower than 50 ml/min Arterial hypertension, ischemic heart disease in acute phase Gastrointestinal diseases, liver diseases in acute phase History of drug and alcohol abuse Patient with history of tendon disorders related to fluoroquinolone administration Pregnancy and breastfeeding women Immune system disorders related to chemotherapy, AIDS, long term administration of corticosteroids The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
</DOC>